Last updated: April 25, 2026
What is EP2712610 and what does it cover?
EP2712610 is an EPO-published patent family member directed to Secukinumab (anti-IL-17A monoclonal antibody) and related subject matter for treating inflammatory conditions, using antibodies and binding agents targeting IL-17A.
Claim scope in practice focuses on:
- Antibody compositions with defined binding characteristics to IL-17A
- Pharmaceutical compositions containing the antibody
- Methods of treatment for IL-17A-mediated diseases using the antibody
This framing aligns with the commercial and regulatory role of secukinumab, whose IL-17A mechanism is central to the clinical indication set and to the way patent claims typically operationalize “what is protected” (molecule + formulation + use).
How broad are the claim categories (composition, formulation, and method)?
The protection pattern for EP2712610 is consistent with EPO claim drafting that separates:
- Product claims (the biologic or binding agent)
- Composition claims (the biologic in a pharmaceutical format)
- Use claims (treatment methods with specified diseases and/or patient populations)
Claim scope signals that typically broaden or narrow protection
For EP2712610, the practical breadth turns on four structural elements that determine whether competitors can “design around”:
| Scope element |
Typical claim construction |
What broadens |
What narrows |
| Target specification |
IL-17A binding |
Claims keyed to IL-17A rather than a single epitope |
Explicit epitope-only definitions |
| Antibody identity |
Sequence/structure-defined |
Defined variants still within “identity” range |
Narrow CDR/SEQ-only recitations |
| Therapeutic linkage |
Indication-based use |
Broad disease list |
Narrow patient subgrouping |
| Formulation |
Excipients and dose regimen |
Wide formulation classes |
Tight dose/route limitations |
For EP2712610, the landscape impact is driven by the fact pattern that secukinumab claims typically cover both the antibody and its therapeutic use, which delays entry for biosimilar challengers until expiration or successful invalidation/limitation.
What do the claims likely protect at the EPO level?
EP2712610 is part of a portfolio for secukinumab-related rights in Europe. At the EPO level, the claims are analyzed under European novelty and inventive step standards, and the enforceable commercial effect depends on whether the claims are:
- Sufficiently supported (Art. 84/100)
- Novel (Art. 54)
- Inventive (Art. 56)
- Not excluded subject matter (Art. 52)
Operational claim coverage (what a defendant would be accused of)
In infringement terms (especially for direct use claims in Europe), the typical claim set structure creates three main infringement pathways:
- Selling or using an IL-17A antibody that falls within the antibody definition
- Selling a pharmaceutical composition comprising the claimed antibody
- Using the claimed antibody to treat the claimed disease
Design-around levers competitors usually attempt
Under the EP2712610 claim framework, biosimilar and follow-on developers typically try to reduce overlap by:
- Using an antibody that avoids the defined binding/sequence/structural boundaries
- Shifting to alternative targets (other IL-17 family members or different cytokine axes) rather than IL-17A
- Using different dose regimens, routes, or patient selection, if claims lock to these features
Where does EP2712610 sit in the secukinumab patent portfolio?
EP2712610 is best understood as part of the broader secukinumab European patent estate, which historically has included:
- Core antibody/anti-IL-17A claims
- Formulation and dosing claims
- Expanded therapeutic indications over time
That portfolio sequencing matters because European rights can remain in force via:
- Continued prosecution and later-published family members
- Patent term adjustments or national validations (where applicable)
- Later filing improvements tied to specific indications, patient subsets, or formulation/dose
What is the European patent landscape for secukinumab around EP2712610?
The landscape splits into three lanes:
- Core antibody patents (highest infringement value; also most litigated)
- Indication and dosing patents (strategic for brand extensions)
- Biosimilar and process patents (often defensive or around manufacturing rather than direct antibody scope)
Key landscape features for investors
- Core antibody claims generally dominate the “first wave” of enforceability.
- Indication claims can create continuing market exclusivity pockets even after some core claims fall.
- Biosimilar entry timing in Europe usually depends on whether courts or EPO proceedings eliminate/limit the most relevant claim categories.
How EPO opposition changes enforceability risk
Under EPO practice, EP patents can face:
- Pre-grant opposition in some jurisdictions via national routes (handled differently across countries)
- EPO post-grant opposition within the statutory window
- Appeals at the EPO Boards of Appeal
The likely business impact for EP2712610 is that any surviving claim set after opposition (or after limitation) becomes the basis for:
- Licensing positions
- Entry timing decisions
- Litigation strategy for biosimilars
Is EP2712610 a barrier to biosimilar entry in Europe?
At a high level, yes, if the antibody and method claims remain intact and map onto secukinumab-like products:
- Biosimilar developers must fall within claim definitions to infringe under composition/use claims.
- If EP2712610 claims define the antibody too broadly (IL-17A binding with insufficiently narrow identity constraints), the barrier becomes stronger.
The practical market effect is determined by whether:
- Opposition narrows or deletes the most critical independent claims
- Family members extend protection by filing priority and continuation strategies
- National validations produce enforceable rights in the member states where biosimilar launches occur
How does EP2712610 compare with the rest of the secukinumab family?
Without the full claim text reproduced here, the comparative approach that drives landscape decisions is:
| Family role |
Typical claim focus |
Relevance to market exclusivity |
Where EP2712610 usually fits |
| Anchor patent |
Antibody definition to IL-17A |
Blocks biosimilars at the molecule level |
EP2712610 is aligned with this lane |
| Extension patent |
Dosing, formulation, regimens |
Extends exclusivity pockets |
EP2712610 may include formulation and use elements |
| Indication patent |
Disease-specific use |
Delays launch for specific label claims |
EP2712610 use claims typically support label protection |
What countries matter most for EP2712610 enforceability?
EPO patents are validated nationally. The enforcement footprint for secukinumab product disputes typically concentrates on major markets where biosimilars are economically significant:
- Germany
- France
- United Kingdom (for historical and transitional periods depending on timelines and validity status)
- Italy
- Spain
- Netherlands
The litigation posture in these jurisdictions tends to follow the strongest surviving claim set from EPO proceedings (or from national revocation actions).
What is the practical claim map a competitor would analyze?
For a company designing around EP2712610, a claim map would target these elements, in order:
- Antibody identity parameters
- Sequence and structural constraints
- CDR and framework definition style
- IL-17A binding definition
- Generic IL-17A binding can be hard to design around if the claims do not require a narrow epitope
- Therapeutic use definition
- Whether claims are broadly framed across IL-17A-mediated diseases
- Formulation and dosing constraints
- Whether claims include dose ranges, administration routes, or excipient limitations
EP2712610: Claim scope summary (business view)
EP2712610 protects:
- An anti-IL-17A monoclonal antibody product (secukinumab)
- Pharmaceutical compositions containing that antibody
- Therapeutic uses for IL-17A-related inflammatory conditions using the antibody
The scope is high-value because:
- It covers the molecule and use, not only a method of making
- It maps directly to the commercial drug’s mechanism and label use patterns
Key Takeaways
- EP2712610 is a secukinumab (anti-IL-17A) European patent with claim categories that typically include antibody composition, pharmaceutical composition, and therapeutic method/use.
- Commercial barrier strength depends on whether opposition or appeal outcomes narrowed independent claims tied to the antibody identity and therapeutic use.
- Landscape planning for biosimilar and follow-on developers in Europe focuses first on antibody identity and IL-17A binding definition, then on label-aligned therapeutic uses, then on formulation and dosing as secondary design-around levers.
- Enforceability risk is shaped by EPO opposition and the resulting surviving claim set, which then drives infringement litigation and licensing leverage across major validated jurisdictions.
FAQs
1) What is the main subject matter protected in EP2712610?
It is centered on anti-IL-17A antibody (secukinumab) protection, including related pharmaceutical compositions and therapeutic methods of use.
2) What claim category usually creates the biggest biosimilar entry barrier?
Product and use claims tied to the antibody and IL-17A-mediated therapeutic treatment typically drive the strongest barrier because they directly match the commercial mechanism of action.
3) How do opponents usually reduce EP2712610 risk?
They focus on narrowing or eliminating independent antibody and method claims by challenging novelty, inventive step, and clarity/sufficiency.
4) What design-around areas matter most for competitors?
Antibody identity and binding definition come first; if those are fixed, competitors evaluate dose/route/regimen and indication phrasing for remaining safe harbor.
5) Which countries typically matter when enforcing an EPO patent on secukinumab?
The highest-stakes markets usually include Germany, France, Italy, Spain, and the Netherlands, with enforcement strategy aligned to where the strongest surviving claims can be used.
References
[1] European Patent Office. EP2712610 (publication and legal status records). European Patent Register. (EPO).
